Extended Data Fig. 2: Mean HLA-I evolutionary divergence is associated with improved benefit from immune checkpoint inhibitors.
From: Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
a, Association of high mean HED (red) with improved efficacy of anti-CTLA-4 treatment in a cohort of patients with metastatic melanoma; P = 0.0072; two-sided log-rank test. Density plots indicate the distribution of mean HED and cutoff used in the survival curves. T.Q.C. = top quartile cutoff, HR = hazard ratio, CI = confidence interval. b, Association of high (top quartile) tumor mutational burden (TMB) with overall survival after anti-CTLA-4 treatment; P = 0.20; two-sided log-rank test. c, Association of high mean HED and high TMB (red) with improved overall survival after anti-CTLA4 treatment; P = 0.024; two-sided log-rank test. d, Multivariable Cox proportional-hazards model including mean HED and other clinical variables. Data show independent effect of mean HED associated with improved survival after anti-CTLA-4. HED, TMB, and fraction of copy number alterations (FCNA) are dichotomized into high (1) and low (0) groups based on the top quartile for each variable. P values calculated using two-sided log-rank test. Horizontal lines represent the 95% confidence interval.
